Search clinical trials for: Invasive mole

Total 106505 results

National Cancer Institute (NCI)

Active, not recruiting

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Malignant Solid Neoplasm | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Breast Adenocarcinoma

United States
Dana-Farber Cancer Institute
Pfizer

Active, not recruiting

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Breast Cancer

United States
University of Utah
Bristol-Myers Squibb

Active, not recruiting

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)

Bladder Cancer

United States
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
AstraZeneca

Active, not recruiting

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)

Muscle Invasive Bladder Cancer

Spain, United States, Canada, France, United Kingdom
Clinical Hospital Centre Zagreb

Active, not recruiting

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

Croatia
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Renal Cell Carcinoma
Fondazione Michelangelo
Hoffmann-La Roche

Active, not recruiting

Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)

Invasive Breast Cancer

Spain, Italy, Germany, Austria
Fondazione Michelangelo

Completed

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1)

Invasive Ductal Breast Carcinoma

Spain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
National Cancer Institute (NCI)

Withdrawn

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

Urothelial Carcinoma | Renal Pelvis and Ureter Urothelial Carcinoma | Bladder Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

Canada
Scynexis, Inc.

Completed

Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)

Invasive Pulmonary Aspergillosis

United States, Belgium, Canada, Germany, South Africa
University of Texas Southwestern Medical Center
Cancer Prevention Research Institute of Texas

Active, not recruiting

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Breast Cancer Female

United States
Region Skane

Completed

Minimally Invasive Benign Hysterectomy

Metrorrhagia | Uterine Fibroids | Menorrhagia | Cervical Dysplasia

Sweden
University of Alabama at Birmingham

Withdrawn

A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning (O-15 Water)

Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging

United States
St. Joseph's Healthcare Hamilton
Hamilton Academic Health Sciences Organization

Active, not recruiting

Non-invasive Ventilation and Dex in Critically Ill Adults (inDEX)

Respiratory Insufficiency

Saudi Arabia, Canada, Australia
University of Texas Southwestern Medical Center
Boehringer Ingelheim

Completed

Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction

Diabetes Mellitus | Heart Failure, Diastolic | Heart Failure With Preserved Ejection Fraction

United States
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Breast Cancer

United States
Beth Israel Deaconess Medical Center
Johns Hopkins University; Dana-Farber Cancer Institute; AstraZeneca

Active, not recruiting

Olaparib In Metastatic Breast Cancer

Metastatic Breast Cancer | Invasive Breast Cancer | BRIP1 Gene Mutation | PALB2 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | Somatic Mutation Breast Cancer (BRCA1) | Somatic Mutation Breast Cancer (BRCA2)

United States
H. Lee Moffitt Cancer Center and Research Institute
Amgen

Active, not recruiting

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
M.D. Anderson Cancer Center

Completed

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Halozyme Therapeutics

Completed

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
CG Oncology, Inc.; Richard M. Shulze Family Foundation

Active, not recruiting

Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC

Bladder Cancer | Muscle-Invasive Bladder Carcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Bladder Cancer

United States
Charles University, Czech Republic
Faculty Hospital Kralovske Vinohrady

Completed

Celecoxib in Postoperative Analgesia for Radius Fracture Surgery

Pain, Postoperative

Czechia
Marmara University

Completed

The Effect Of High And Low Molecular Weight Sodium Hyaluronic Acid Eye Drops After Crosslinking

Keratoconus

Turkey
Guarionex J. Decastro
Sanofi

Active, not recruiting

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder (CGC)

Urothelial Carcinoma of the Urinary Bladder

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Syndax Pharmaceuticals

Active, not recruiting

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Bladder Cancer

United States
Aalborg University Hospital
Aarhus University Hospital; Rigshospitalet, Denmark; Horsens Hospital; Kolding... and other collaborators

Completed

Cell Based Non Invasive Prenatal Testing as an Alternative to Chorionic Villus Sampling Following Preimplantation Genetic Testing

Preimplantation Genetic Diagnosis | Prenatal Diagnoses

Denmark
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms | Muscle-Invasive Bladder Cancer

Russian Federation, United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Portugal, Roman... and more
Merck Sharp & Dohme LLC
Astellas Pharma Inc; Seagen Inc.

Active, not recruiting

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

Bladder Cancer

Hungary, United States, China, Argentina, Australia, Bulgaria, Canada, Colombia, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Malaysia, Philippines, Poland, Portugal, Romania, Russian Federation, Singapo... and more
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Invasive Pulmonary Aspergillosis | Fungal Infections
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Gastric Neuroendocrine Carcinoma | Intestinal Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Invasive Aspergillosis

Belgium, United States, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Active, not recruiting

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Triple Negative Breast Cancer | Invasive Breast Cancer | Stage IV Breast Cancer | HER2 Negative

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Urinary Bladder Neoplasms

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
University of Nebraska
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditions

United States
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Non-Small Cell Lung Cancer

Poland, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Romania, Russian Federation, Spain, Switzerland, Taiwan, Turkey, Ukr... and more
Laura Kennedy
National Cancer Institute (NCI)

Suspended

Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

Breast Cancer | Triple-negative Breast Cancer

United States
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
UNICANCER
Hoffmann-La Roche

Active, not recruiting

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN)

Bladder Cancer

Spain, France, Belgium
University of Chicago
Guerbet

Completed

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

Breast Cancer | Breast Neoplasms | Breast Diseases | Breast Fibroadenoma

United States
Universitätsklinikum Hamburg-Eppendorf
Cancer Research UK; Deutsche Krebshilfe e.V., Bonn (Germany); Australasian Gastro-Intestinal... and other collaborators

Active, not recruiting

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)

Cholangiocarcinoma | Gall Bladder Carcinoma

Germany, Netherlands, United Kingdom, Australia, Denmark, Italy, New Zealand, Austria
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Ductal Breast Carcinoma

United States

Search clinical trials for: Invasive mole

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations